WO2003082911A3 - Utilisation de la proteine maba (fabg1) de mycobacterium tuberculosis pour la conception et le criblage d'antibiotiques - Google Patents

Utilisation de la proteine maba (fabg1) de mycobacterium tuberculosis pour la conception et le criblage d'antibiotiques Download PDF

Info

Publication number
WO2003082911A3
WO2003082911A3 PCT/FR2003/000990 FR0300990W WO03082911A3 WO 2003082911 A3 WO2003082911 A3 WO 2003082911A3 FR 0300990 W FR0300990 W FR 0300990W WO 03082911 A3 WO03082911 A3 WO 03082911A3
Authority
WO
WIPO (PCT)
Prior art keywords
fabg1
designing
proteins
mycobacterium tuberculosis
protein
Prior art date
Application number
PCT/FR2003/000990
Other languages
English (en)
Other versions
WO2003082911A2 (fr
Inventor
Annaik Quemard
Gilles Labesse
Mamadou Daffe
Hedia Marrakchi
Dominique Douguet
Martin Cohen-Gonsaud
Stephanie Ducasse
Original Assignee
Centre Nat Rech Scient
Inst Nat Sante Rech Med
Univ Montpellier 1
Annaik Quemard
Gilles Labesse
Mamadou Daffe
Hedia Marrakchi
Dominique Douguet
Martin Cohen-Gonsaud
Stephanie Ducasse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Inst Nat Sante Rech Med, Univ Montpellier 1, Annaik Quemard, Gilles Labesse, Mamadou Daffe, Hedia Marrakchi, Dominique Douguet, Martin Cohen-Gonsaud, Stephanie Ducasse filed Critical Centre Nat Rech Scient
Priority to EP03740540A priority Critical patent/EP1490491B1/fr
Priority to DE60312497T priority patent/DE60312497T2/de
Priority to AU2003258723A priority patent/AU2003258723A1/en
Priority to US10/503,939 priority patent/US20060035294A1/en
Publication of WO2003082911A2 publication Critical patent/WO2003082911A2/fr
Publication of WO2003082911A3 publication Critical patent/WO2003082911A3/fr
Priority to US12/423,586 priority patent/US20100240084A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention a principalement pour objet la protéine MabA, encore désignée protéine FabG1, recombinante sous forme purifiée, ou les protéines recombinantes dérivées de la protéine MabA par mutation d'un ou plusieurs acides aminés, ainsi que leurs utilisations, ainsi que de leurs coordonnées cristallographiques, dans le cadre de la mise en oeuvre de méthodes de conception et de criblage de ligands de ces protéines, et avantageusement de ligands inhibiteurs de l'activité enzymatique de ces protéines.
PCT/FR2003/000990 2002-03-29 2003-03-28 Utilisation de la proteine maba (fabg1) de mycobacterium tuberculosis pour la conception et le criblage d'antibiotiques WO2003082911A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03740540A EP1490491B1 (fr) 2002-03-29 2003-03-28 Utilisation de la proteine maba (fabg1) de mycobacterium tuberculosis pour la conception et le criblage d'antibiotiques
DE60312497T DE60312497T2 (de) 2002-03-29 2003-03-28 Verwendung von protein maba (fabg1) aus mycobacterium tuberculosis zur herstellung und nachweis von antibiotika
AU2003258723A AU2003258723A1 (en) 2002-03-29 2003-03-28 Use of the protein maba (fabg1) of less thanigreater thanmycobacterium tuberculosisless than/igreater than for designing and screening antibiotics
US10/503,939 US20060035294A1 (en) 2002-03-29 2003-03-28 Use of the protein maba (fabg1) of mycobacterium tuberculosis for designing and screening antibiotics
US12/423,586 US20100240084A1 (en) 2002-03-29 2009-04-14 Use of the protien maba (fabg1) of mycobacterium tuberculosis for designing and screening antibiotics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204018A FR2837836B1 (fr) 2002-03-29 2002-03-29 UTILISATION DE LA PROTEINE Maba (FABG1) DE MYCOBACTERIUM TUBERCULOSIS POUR LA CONCEPTION ET LE CRIBLAGE D'ANTIBIOTIQUES
FR02/04018 2002-03-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/423,586 Division US20100240084A1 (en) 2002-03-29 2009-04-14 Use of the protien maba (fabg1) of mycobacterium tuberculosis for designing and screening antibiotics

Publications (2)

Publication Number Publication Date
WO2003082911A2 WO2003082911A2 (fr) 2003-10-09
WO2003082911A3 true WO2003082911A3 (fr) 2004-04-01

Family

ID=27839347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/000990 WO2003082911A2 (fr) 2002-03-29 2003-03-28 Utilisation de la proteine maba (fabg1) de mycobacterium tuberculosis pour la conception et le criblage d'antibiotiques

Country Status (8)

Country Link
US (2) US20060035294A1 (fr)
EP (1) EP1490491B1 (fr)
AT (1) ATE356872T1 (fr)
AU (1) AU2003258723A1 (fr)
DE (1) DE60312497T2 (fr)
ES (1) ES2283790T3 (fr)
FR (1) FR2837836B1 (fr)
WO (1) WO2003082911A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1996611A1 (fr) * 2006-03-23 2008-12-03 Centre National de la Recherche Scientifique Complexes de nadp avec la protéine maba de mycobacterium tuberculosis ou avec des mutants de ce dernier, et leurs applications dans la conception et le criblage d'antibiotiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026765A1 (fr) * 1993-05-13 1994-11-24 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Utilisation des genes de m. tuberculosis, m. bovis et m. smegmatis conferant une resistance a l'isoniazide
WO1994026312A1 (fr) * 1993-05-13 1994-11-24 Jacobs William R Jr PROCEDES ET COMPOSITIONS DE DETECTION ET DE TRAITEMENT DES INFECTIONS MYCOBACTERIENNES AU MOYEN D'UN GENE inhA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026765A1 (fr) * 1993-05-13 1994-11-24 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Utilisation des genes de m. tuberculosis, m. bovis et m. smegmatis conferant une resistance a l'isoniazide
WO1994026312A1 (fr) * 1993-05-13 1994-11-24 Jacobs William R Jr PROCEDES ET COMPOSITIONS DE DETECTION ET DE TRAITEMENT DES INFECTIONS MYCOBACTERIENNES AU MOYEN D'UN GENE inhA

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A BANERJEE ET AL.: "The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance", MICROBIOLOGY, vol. 144, no. 10, October 1998 (1998-10-01), CONSULTANTS BUREAU, NEW YORK, NY, US, pages 2697 - 2704, XP002229443, ISSN: 0026-2617 *
A C PRICE ET AL.: "Structure of beta-ketoacyl-[acyl carrier protein] reductase from Escherichia coli: negative cooperativity and its structural basis", BIOCHEMISTRY., vol. 40, no. 43, 2001, AMERICAN CHEMICAL SOCIETY. EASTON, PA., US, pages 12772 - 12781, XP002229444, ISSN: 0006-2960 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, P KIEPIELA ET AL: "Genomic mutations in the katG, inhA and aphC are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa", XP002229447, Database accession no. PREV200000182099 *
H MARRAKCHI ET AL.: "MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II", MICROBIOLOGY, vol. 148, no. 4, April 2002 (2002-04-01), CONSULTANTS BUREAU, NEW YORK, NY, US, pages 951 - 960, XP002229445, ISSN: 0026-2617 *
M COHEN-GONSAUD ET AL.: "Crystal structure and fluorescence spectroscopy of MabA from Mycobacterium tuberculosis, a reductase involved in long-chain fatty acid biosynthesis", BIOPHYSICAL JOURNAL, vol. 82, no. 1 part 2, January 2002 (2002-01-01), NEW YORK, US, US, pages 453A, XP002229792, ISSN: 0006-3495 *
M COHEN-GONSAUD ET AL.: "Crystal structure of MabA from Mycobacterium tuberculosis, a reductase involved in long-chain fatty acid biosynthesis", JOURNAL OF MOLECULAR BIOLOGY, vol. 320, no. 2, 5 July 2002 (2002-07-05), LONDON, GB, pages 249 - 261, XP002229446, ISSN: 0022-2836 *
TUBERCLE AND LUNG DISEASE, vol. 80, no. 1, 2000, pages 47 - 56 *

Also Published As

Publication number Publication date
ES2283790T3 (es) 2007-11-01
AU2003258723A1 (en) 2003-10-13
EP1490491B1 (fr) 2007-03-14
DE60312497T2 (de) 2007-09-20
EP1490491A2 (fr) 2004-12-29
ATE356872T1 (de) 2007-04-15
FR2837836A1 (fr) 2003-10-03
AU2003258723A8 (en) 2003-10-13
DE60312497D1 (de) 2007-04-26
WO2003082911A2 (fr) 2003-10-09
US20100240084A1 (en) 2010-09-23
US20060035294A1 (en) 2006-02-16
FR2837836B1 (fr) 2005-04-22

Similar Documents

Publication Publication Date Title
WO2007004876A3 (fr) Peptides inhibant l'enzyme de conversion d'angiotensine
EP1801206A4 (fr) Methode de synthese de la l-arginine, de la l-ornithine, ou de la l-citrulline
HUP0105331A2 (hu) Új karbonil-reduktáz, ennek génje és alkalmazásának módszere
AU2002354696A1 (en) Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme
WO2007058267A8 (fr) Proteine innovante et gene codant pour la proteine
WO2003082911A3 (fr) Utilisation de la proteine maba (fabg1) de mycobacterium tuberculosis pour la conception et le criblage d'antibiotiques
WO2008146259A3 (fr) Clivage spécifique de malt1 dans un procédé de dosage et de criblage
WO2002093177A3 (fr) Analyses, methodes et dispositifs
WO2003070229A3 (fr) Utilisation d'inhibiteurs de proteinases pour le traitement de maladies auto-immunes
AU4871993A (en) Dictyostelium dipeptidylaminopeptidase
WO2004024765A8 (fr) Structure de cristal d'une enzyme de conversion de l'angiotensine (ace) et ses utilisations
WO2007014951A3 (fr) Procedes de criblage de substances antibacteriennes
MY150639A (en) T cell adhesion molecule and antibody thereto
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
DK0828004T3 (da) Proteindisulfidisomerase-gen afledt af stamme af methylotrof gær
DE60121225D1 (de) Tetrapeptidische tryptase substrate und ihre verwendung zur tryptase aktivitätbestimmung
WO2003054194A3 (fr) Tridegines modifiees, leur production et leur utilisation comme inhibiteurs de transglutaminase
WO2006136982A3 (fr) Polypeptide isole de la proteine de controle du complement du virus vaccinal de recombinaison (hrvcp)
WO2002083729A3 (fr) Polypeptides, leurs derives et leurs utilisations
EP1536010A4 (fr) Medicaments destines a la prevention et au traitement du cancer
WO2005003289A3 (fr) Variants de l'amine oxydase ap1
WO2004042043A3 (fr) Structures cristallines de 3-epimerases bacteriennes de ribulose-phosphate
WO2003070769A3 (fr) Composes organiques
WO2002061074A1 (fr) Nouvelle proteine et adn la comprenant
WO2006067406B1 (fr) Fragments de peptides immunomodulateurs de cd23 et utilisations correspondantes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003740540

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003740540

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006035294

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10503939

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10503939

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2003740540

Country of ref document: EP